NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

A statistically significant, 37.4% difference (P=0.03), slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo, in the...

Related Keywords

Israel ,Cambridge ,Cambridgeshire ,United Kingdom ,Italy ,Canada , ,Linkedin ,Nasdaq ,Neurosense Therapeutics Ltd ,Drug Administration ,European Medicines Agency ,Per Protocol ,Neurosense Therapeutics ,Rating Scale Revised ,Slow Vital Capacity ,Investigator Initiated ,Scientific Advice ,Alon Ben Noon ,Orphan Drug Designation ,European Medicines ,Sense Therapeutics ,Neurosense ,